Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …

Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer.
However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective …

Simple Summary Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors
(PARPi) are effective against tumors with mutations in DNA repair genes, most commonly in …

There is emerging evidence about the predictive role of homologous recombination
deficiency (HRD), but this is less defined in gastrointestinal (GI) and thoracic malignancies …

Background Homologous recombination is a robust, broadly error-free mechanism of double-
strand break repair, and deficiencies lead to PARP inhibitor sensitivity. Patients displaying …

DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and
transcription if left unrepaired. The cellular response to ICLs requires the coordination of …

Synthetic lethality is a genetic phenomenon whereby the simultaneous presence of two
different genetic alterations impairs cellular viability. Importantly, targeting synthetic lethal …

The field of cancer genomics and transcriptomics has evolved from targeted profiling to swift
sequencing of individual tumor genome and transcriptome. The steady growth in genome …

Simple Summary Cancer is the second most common cause of death in the USA. Genomic
instability is one of the well-established hallmarks of cancer. The homologous recombination …

PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-
negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi) …